All sponsors

Shanghai Henlius Biotech $2696.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS35
PHASE 3 / 2-313
RECRUITING18
READOUTS ≤12 MONTHS15
READOUT SLIPPED >6 MO14%

Delay Index: of 21 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shanghai Henlius Biotech on the live radar map → 📅 $2696.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
HLX10
NCT04301739
P3Not yet recruitingTriple Negative Breast Cancer5222022-09-07
HLX11
NCT05346224
P3Active, not recruitingBreast Cancer; Breast Neoplasms9002024-05-15 (+5 mo)
HLX10
NCT04547166
P2/3RecruitingMetastatic Colorectal Cancer5682025-09-24
HLX26
NCT05787613
P2Active, not recruitingNSCLC Stage IV1322026-02 (+7 mo)
Serplulimab + chemotherapy (carboplatin-etoposide)
NCT05468489
P2Active, not recruitingExtensive Stage Small Cell Lung Cancer2002026-02-28 (+21 mo)
HLX10
NCT05353257
P3Active, not recruitingLimited-Stage Small Cell Lung Cancer5112026-06-30 (+18 mo)
HLX43 DOSE 1
NCT07269782
P2RecruitingNon Small Cell Lung Cancer602026-07-10
HLX10+chemo
NCT06812260
P2Active, not recruitingSCLC, Extensive Stage262026-10-22 (+2 mo)
HLX43 dose 1
NCT06848699
P1/2RecruitingSolid Tumor Cancer; Non Small Cell Lung Cancer1052026-10-30
HLX43 DOSE 1
NCT06742892
P2RecruitingCarcinoma, Hepatocellular902026-10-31
HLX43
NCT06769113
P2RecruitingEsophageal Cancer1022026-10-31
HLX43 DOSE 1
NCT06839066
P2RecruitingNasopharyngeal Carcinoma (NPC)702026-11-22
HLX43 Dose 1;
NCT07106892
P2RecruitingColorectal Cancer (CRC)602026-12-30
HLX43
NCT07459738
P2Not yet recruitingHormone Receptor Positive HER-2 Negative Breast Cancer602026-12-30
HLX43
NCT06769152
P2RecruitingCervical Cancer; Ovarian Cancer1902026-12-31 (+2 mo)
NCT07038382
NCT07038382
P2RecruitingMembranous Nephropathy; Lupus Nephritis (LN)242027-01
HLX53 (1000mg)
NCT06349980
P2RecruitingCarcinoma, Hepatocellular1172027-02-10
HLX17
NCT06847334
P3Not yet recruitingNon-Squamous Non-Small Cell Lung Cancer7722027-04-09
HLX43 DOSE 1 IN ≥2L TNBC
NCT07487519
P2Not yet recruitingBreast Cancer (Triple Negative Breast Cancer (TNBC))1802027-05-15
HLX22
NCT06532006
P3RecruitingGastroesophageal-junction Cancer; Monoclonal Antibody5502027-06-01
HLX22
NCT06832202
P2RecruitingHER2-low Hormone Receptor Positive Breast Cancer502027-06-01
HLX13
NCT06841185
P3Not yet recruitingHepatocellular Carcinoma (HCC)6562027-06-06
HLX43 dose 1
NCT07253142
P2RecruitingNon Small Cell Lung Cancer; Small Cell Lung Cancer1202027-06-18
HLX15-IV
NCT06895512
P3Not yet recruitingNewly Diagnosed Multiple Myeloma3862027-07
HLX43 dose 1 + HLX07
NCT07358585
P1/2Not yet recruitingColon Cancer Adenocarcinoma1262027-07-28
HLX43 DOSE 1
NCT07115485
P2RecruitingGastric or Gastroesophageal Junction Adenocarcinoma602027-08-30
HLX43 DOSE 1
NCT06857279
P2RecruitingCarcinoma of Head and/or Neck1672027-12-30 (+2 mo)
HLX87 + HLX22
NCT07294508
P2/3RecruitingHER2 + Breast Cancer7062028-01-15
HLX43 DOSE 1 (2.5 mg/kg)
NCT07301229
P2Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)1002028-02-21
HLX22
NCT07824869
P2Not yet recruitingHER2 + Breast Cancer902028-03-31
HLX43 DOSE 1 (2.0 mg/kg)
NCT06907615
P2RecruitingNon Small Cell Lung Cancer2432028-04-20
HLX87+HX22
NCT07294534
P2/3Not yet recruitingHER2 + Breast Cancer8172028-09-30
HLX43
NCT07459751
P2/3RecruitingAdvanced or Metastatic Squamous Non-Small Cell Lung Cancer7062030-01-15
Investigational drug: HLX37 dose1, IV, Q3W
NCT07865910
P2/3Not yet recruitingNSCLC (Advanced Non-small Cell Lung Cancer)14382030-12-30
HLX07
NCT07318883
P2/3Not yet recruitingSquamous NSCLC7202031-01